Clonal evolution and branching models
Peter Nowell's 1976 idea that a tumour is an evolving population of competing clones is now measured directly by sequencing several regions or repeated blood samples, and models of branching evolution predict which clones will drive relapse.
Overview
Nowell proposed that tumours arise from a single cell and evolve by mutation and selection into a branching tree of clones. Multi-region sequencing (TRACERx in lung cancer, from 2017) and longitudinal circulating tumour DNA confirmed branched evolution, showed truncal versus subclonal mutations, and revealed that some tumours evolve neutrally while others show strong selective sweeps. Models built on these data estimate mutation rates, timing of metastasis and the likelihood that a subclone carries resistance, and inform which mutations to target (truncal) and how to read residual disease.
How it works
A tumour is a population under mutation, drift and selection; phylogenetic and branching-process models reconstruct its history from the variant allele frequencies observed across regions and time.
- Directly supported by multi-region and serial sequencing
- Distinguishes truncal from subclonal targets
- Quantifies intratumour heterogeneity
- Sampling misses small clones
- Neutral versus selected evolution is debated
- Costly to measure in routine care
Latest papers
topQuery for this technology: (TITLE:"Clonal evolution and branching models" OR ABSTRACT:"Clonal evolution and branching models") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Clonal evolution and branching models, not a curated reading list.
Similar pages
not linked directly; found by shared links- TechnologyMetastatic seeding and dormancy models
Shares Tumour clonal evolution tracking, Continuous and near-continuous ctDNA monitoring and the tag mathematical-model.
- TechnologyEvolutionary game theory in cancer
Shares Tumour clonal evolution tracking and the tag mathematical-model.
- TechnologyGoldie-Coldman model of resistance
Shares Tumour clonal evolution tracking and the tag mathematical-model.
- TechnologyResidual disease kinetics (BCR-ABL halving and ctDNA slopes)
Shares Continuous and near-continuous ctDNA monitoring, Non-small-cell lung cancer and the tag mathematical-model.
- TechnologyEvolutionary dynamics of drug resistance
Shares Tumour clonal evolution tracking and the tag mathematical-model.
- TechnologyTumour volume doubling time
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag mathematical-model.
- TechnologyAdaptive therapy (evolution-based dosing)
Shares Tumour clonal evolution tracking and the tag mathematical-model.
- TechnologyThe four Rs and accelerated repopulation
Shares Non-small-cell lung cancer and the tag mathematical-model.